The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
Open accessAbstract
HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers. We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreated, HER2-expressing (IHC ≥ 1+), non-breast/non-gastric or HER2-mutant solid tumors from a phase I trial (NCT02564900). Most common (>50%) treatment-emergent adverse events (TEAE) were nausea, decreased appetite, and vomiting. Two drug-related TEAEs were associated with fatal outcomes. The confirmed objective response rate (ORR) was 28.3% (17/60). Median progression-free survival (PFS) was 7.2 [95% confidence interval (CI), 4.8–11.1] months. In HER2-mutant non–small cell lung cancer (NSCLC), ORR was 72.7% (8/11), and median PFS was 11.3 (95% CI, 8.1–14.3) months. Confirmed responses were observed in six tumor types, including HER2-expressing NSCLC, colorectal cancer, salivary gland cancer, biliary tract cancer, endometrial cancer, and HER2-mutant NSCLC and breast cancer. Results suggest T-DXd holds promise for HER2-expressing/mutant solid tumors. Significance: T-DXd demonstrated promising activity in a heterogeneous patient population with heavily pretreated HER2-expressing or HER2-mutant solid tumors, especially HER2-mutant NSCLC. The safety profile was generally acceptable. Interstitial lung disease can be severe and requires prompt monitoring and intervention. Further research of T-DXd is warranted to address these unmet medical needs. See related commentary by Rolfo and Russo, p. 643. This article is highlighted in the In This Issue feature, p. 627
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Self-citationTrastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Self-citationTargeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J., Chirieac, L. R., D'Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,303
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
Intragenic ERBB2 kinase mutations in tumours
Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., Stevens, C., O'Meara, S., Smith, R., Parker, A., et al. (2004) · Nature · doi:10.1038/431525b · Cited by 802
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., et al. (2018) · Nature · doi:10.1038/nature25475 · Cited by 780
Self-citationOgitani, Y., Hagihara, K., Oitate, M., Naito, H., & Agatsuma, T. (2016) · Cancer Science · doi:10.1111/cas.12966 · Cited by 751
Krop, I. E., Kim, S.-B., González-Martín, A., LoRusso, P. M., Ferrero, J.-M., Smitt, M., Yu, R., Leung, A. C. F., & Wildiers, H. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70178-0 · Cited by 724
Self-citationSomatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4235 · Cited by 678
Mazières, J., Peters, S., Lepage, B., Cortot, A. B., Barlesi, F., Beau-Faller, M., Besse, B., Blons, H., Mansuet-Lupo, A., Urban, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6095 · Cited by 668 · cited 3×
“HER2 overexpression and/or mutations are also observed in tumors other than breast and gastric cancers, such as non– small cell lung cancer (NSCLC) and colorectal cancer (7, 8).”
BackgroundMeric-Bernstam, F., Hurwitz, H., Raghav, K. P. S., McWilliams, R. R., Fakih, M., VanderWalde, A., Swanton, C., Kurzrock, R., Burris, H., Sweeney, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30904-5 · Cited by 573
Li, B. T., Shen, R., Buonocore, D., Olah, Z. T., Ni, A., Ginsberg, M. S., Ulaner, G. A., Offin, M., Feldman, D., Hembrough, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9777 · Cited by 556
Self-citationBanerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30328-6 · Cited by 547
Fader, A. N., Roque, D. M., Siegel, E., Buza, N., Hui, P., Abdelghany, O., Chambers, S. K., Secord, A. A., Havrilesky, L., O’Malley, D. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.5966 · Cited by 516
Doi, T., Shitara, K., Naito, Y., Shimomura, A., Fujiwara, Y., Yonemori, K., Shimizu, C., Shimoi, T., Kuboki, Y., Matsubara, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30604-6 · Cited by 505
Self-citationWang, S. E., Narasanna, A., Perez-Torres, M., Xiang, B., Wu, F. Y., Yang, S., Carpenter, G., Gazdar, A. F., Muthuswamy, S. K., & Arteaga, C. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.023 · Cited by 470
Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0007-9 · Cited by 468
Drug-Induced Interstitial Lung Disease: A Systematic Review
Skeoch, S., Weatherley, N., Swift, A. J., Oldroyd, A., Johns, C., Hayton, C., Giollo, A., Wild, J. M., Waterton, J. C., Buch, M., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7100356 · Cited by 422
Gatzemeier, U., Groth, G., Butts, C., Van Zandwijk, N., Shepherd, F., Ardizzoni, A., Barton, C., Ghahramani, P., & Hirsh, V. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh031 · Cited by 388
Hussain, M. H. A., MacVicar, G. R., Petrylak, D. P., Dunn, R. L., Vaishampayan, U., Lara, P. N., Chatta, G. S., Nanus, D. M., Glode, L. M., Trump, D. L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0994 · Cited by 376
Tamura, K., Tsurutani, J., Takahashi, S., Iwata, H., Krop, I. E., Redfern, C., Sagara, Y., Doi, T., Park, H., Murthy, R. K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30097-x · Cited by 352
Self-citationKris, M. G., Camidge, D. R., Giaccone, G., Hida, T., Li, B. T., O'Connell, J., Taylor, I., Zhang, H., Arcila, M. E., Goldberg, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv186 · Cited by 334
Self-citationGreulich, H., Kaplan, B., Mertins, P., Chen, T.-H., Tanaka, K. E., Yun, C.-H., Zhang, X., Lee, S.-H., Cho, J., Ambrogio, L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203201109 · Cited by 279
De Grève, J., Teugels, E., Geers, C., Decoster, L., Galdermans, D., De Mey, J., Everaert, H., Umelo, I., Veld, P. I., & Schallier, D. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.01.008 · Cited by 271
Morrison, C., Zanagnolo, V., Ramirez, N., Cohn, D. E., Kelbick, N., Copeland, L., Maxwell, L. G., & Fowler, J. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4827 · Cited by 258
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
Siena, S., Sartore-Bianchi, A., Marsoni, S., Hurwitz, H. I., McCall, S. J., Penault-Llorca, F., Srock, S., Bardelli, A., & Trusolino, L. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy100 · Cited by 244
Robichaux, J. P., Elamin, Y. Y., Vijayan, R. S. K., Nilsson, M. B., Hu, L., He, J., Zhang, F., Pisegna, M., Poteete, A., Sun, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.001 · Cited by 242
Peters, S., Stahel, R., Bubendorf, L., Bonomi, P., Villegas, A., Kowalski, D. M., Baik, C. S., Isla, D., Carpeno, J. D. C., Garrido, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1590 · Cited by 236
Shitara, K., Iwata, H., Takahashi, S., Tamura, K., Park, H., Modi, S., Tsurutani, J., Kadowaki, S., Yamaguchi, K., Iwasa, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30088-9 · Cited by 232
Self-citationHER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium
Pillai, R. N., Behera, M., Berry, L. D., Rossi, M. R., Kris, M. G., Johnson, B. E., Bunn, P. A., Ramalingam, S. S., & Khuri, F. R. (2017) · Cancer · doi:10.1002/cncr.30869 · Cited by 209
Wang, Y., Jiang, T., Qin, Z., Jiang, J., Wang, Q., Yang, S., Rivard, C., Gao, G., Ng, T. L., Tu, M. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy542 · Cited by 207
Heinmöller, P., Groß, C., Beyser, K., Schmidtgen, C., Maass, G., Pedrocchi, M., & Rüschoff, J. (2003) · PubMed · Cited by 204
A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer
Hotta, K., Aoe, K., Kozuki, T., Ohashi, K., Ninomiya, K., Ichihara, E., Kubo, T., Ninomiya, T., Chikamori, K., Harada, D., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.10.032 · Cited by 179
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
Nakada, T., Masuda, T., Naito, H., Yoshida, M., Ashida, S., Morita, K., Miyazaki, H., Kasuya, Y., Ogitani, Y., Yamaguchi, J., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.020 · Cited by 172
Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations
Pahuja, K. B., Nguyen, T. T., Jaiswal, B. S., Prabhash, K., Thaker, T. M., Senger, K., Chaudhuri, S., Kljavin, N. M., Antony, A., Phalke, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.010 · Cited by 164
Liu, L., Shao, X., Gao, W., Bai, J., Wang, R., Huang, P., Yin, Y., Liu, P., & Shu, Y. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f26266 · Cited by 146
ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies
Chuang, J. C., Stehr, H., Liang, Y., Das, M. S., Huang, J. Q., Diehn, M., Wakelee, H. A., & Neal, J. W. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.023 · Cited by 102
Larionov, A. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00089 · Cited by 96
Prognostic value of amplification of c-erb-B2 in bladder carcinoma.
Lönn, U., Lönn, S., Friberg, S. G., Nilsson, B., Silfverswärd, C., & Stenkvist, B. (1995) · PubMed · Cited by 92
Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers
Marx, A. H., Burandt, E., Choschzick, M., Simon, R., Yekebas, E. F., Kaifi, J. T., Mirlacher, M., Atanackovic, D., Bokemeyer, C., Fiedler, W., et al. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.02.018 · Cited by 91
Heymach, J. V., Negrao, M. V., Robichaux, J. P., Carter, B. W., Patel, A. P., Altan, M., Gibbons, D. L., Fossella, F. V., Simon, G. R., Lam, V. K. L., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.243 · Cited by 85
Lai, W. V., Lebas, L., Barnes, T. A., Milia, J., Ni, A., Gautschi, O. P., Peters, S., Ferrara, R., Plodkowski, A. J., Kavanagh, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.030 · Cited by 81
Self-citationSkårderud, M. R., Dyhl-Polk, A., Vistisen, K. K., Larsen, F. O., & Nielsen, D. L. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.011 · Cited by 77
Trifluridine/Tipiracil: An Emerging Strategy for the Management of Gastrointestinal Cancers
Peeters, M., Cervantes, A. M. R., Vera, S. R. M., & Taïeb, J. (2018) · Future Oncology · doi:10.2217/fon-2018-0147 · Cited by 62
Grob, T. J., Kannengießer, I., Tsourlakis, M., Atanackovic, D., Koenig, A. M., Vashist, Y. K., Klose, H. F. E., Marx, A. H., Koops, S., Simon, R., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.125 · Cited by 57
Serra, V., Vivancos, A. P., Puente, X. S., Felip, E., Silberschmidt, D., Caratù, G., Parra, J.-L., Mattos‐Arruda, L. D., Grueso, J., Hernández‐Losa, J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0132 · Cited by 49
The prognostic significance of HER2 overexpression in non-small cell lung cancer.
Takenaka, M., Hanagiri, T., Shinohara, S., Kuwata, T., Chikaishi, Y., Oka, S., Shigematsu, Y., Nagata, Y., Shimokawa, H., Nakagawa, M., et al. (2011) · PubMed · Cited by 38
Powell, C., Camidge, D., Gemma, A., Kusumoto, M., Baba, T., Kuwano, K., Bankier, A. A., Kiura, K., Tamura, K., Modi, S., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-p6-17-06 · Cited by 19
Self-citation
Cited by
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,392
Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D.-Y., Banerjee, S., González-Martín, A., Jung, K. H., Ługowska, I., Manso, L., Manzano, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02005 · Cited by 1,069
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L., Saltos, A. N., Felip, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,021
Self-citationEttinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0013 · Cited by 948
Metadata
- Authors
- Tsurutani, J., Iwata, H., Krop, I., Jänne, P. A., Doi, T., Takahashi, S., Park, H., Redfern, C., Tamura, K., Wise-Draper, T. M., Saito, K., Sugihara, M., Singh, J., Jikoh, T., Gallant, G., & Li, B. T.
- Venue
- Cancer Discovery
- Published
- 2020-05-01
- Volume
- 10
- Issue
- 5
- Pages
- 688-701
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3013632168
- Cited by
- 354
- References
- 50
- FWCI
- 17.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.